Oppenheimer Initiates Coverage of Evommune (EVMN) with Outperform Recommendation
Fintel reports that on January 22, 2026, Oppenheimer initiated coverage of Evommune (NYSE:EVMN) with a Outperform recommendation.
Analyst Price Forecast Suggests 108.32% Upside
As of January 14, 2026, the average one-year price target for Evommune is $39.37/share. The forecasts range from a low of $35.35 to a high of $44.10. The average price target represents an increase of 108.32% from its latest reported closing price of $18.90 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.90.
What is the Fund Sentiment?
There are 5 funds or institutions reporting positions in Evommune. This is an increase of 2 owner(s) or 66.67% in the last quarter.
What are Other Shareholders Doing?
Standard Life Aberdeen holds 525K shares representing 1.67% ownership of the company.
Capricorn Fund Managers holds 60K shares representing 0.19% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.